个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Wu Chengyong[1] ; Zhang Lele[1] ; Zhou Zhilan[1] ; Tan Lun[1] ; Wang Zhijia[1] ; Guo Cuiyu[1] ; Wang Yuxi[1,2] ;
机构： [1]Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China [2]Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, China
出处：
DOI： 10.1016/j.ejmech.2024.116649
ISSN：

关键词： Tubulin Colchicine-binding site inhibitors Crystal structure Thieno[3 2-d]pyrimidine

摘要：
Guided by the X-ray cocrystal structure of the lead compound 4a, we developed a series of thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines demonstrating potent antiproliferative activity against four tumor cell lines. Two analogs, 13 and 25d, exhibited IC50 values around 1 nM and overcame P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). At low concentrations, 13 and 25d inhibited both the colony formation of SKOV3 cells in vitro and tubulin polymerization. Furthermore, mechanistic studies showed that 13 and 25d induced G2/M phase arrest and apoptosis in SKOV3 cells, as well as dose-dependent inhibition of tumor cell migration and invasion at low concentrations. Most notably, the X-ray cocrystal structures of compounds 4a, 25a, and the optimal molecule 13 in complex with tubulin were elucidated. This study identifies thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines as representatives of colchicine-binding site inhibitors (CBSIs) with potent antiproliferative activity.Copyright © 2024 Elsevier Masson SAS. All rights reserved.

基金：
National Natural Science Foundation of China (82073318, 32201226),China Postdoctoral Science Foundation (2022M712273).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
第一作者：
第一作者机构： [1]Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China [2]Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, China
推荐引用方式(GB/T 7714)：
Wu Chengyong,Zhang Lele,Zhou Zhilan,et al.Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy[J].European Journal Of Medicinal Chemistry.2024,276:116649.doi:10.1016/j.ejmech.2024.116649.
APA：
Wu Chengyong,Zhang Lele,Zhou Zhilan,Tan Lun,Wang Zhijia...&Wang Yuxi.(2024).Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.European Journal Of Medicinal Chemistry,276,
MLA：
Wu Chengyong,et al."Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy".European Journal Of Medicinal Chemistry 276.(2024):116649

相关文献

[1]Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. [2]X-ray Crystal Structure-Guided Discovery of Novel Indole Analogues as Colchicine-Binding Site Tubulin Inhibitors with Immune-Potentiating and Antitumor Effects against Melanoma [3]Discovery and biological evaluation of 4,6-pyrimidine analogues with potential anticancer agents as novel colchicine binding site inhibitors [4]A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin [5]Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor. [6]Crystal structure of monkeypox H1 phosphatase, an antiviral drug target [7]Crystal structure and function analysis of 6-phosphogluconate dehydrogenase in Mycobacterium tuberculosis [8]Crystal structure of the novel di-nucleotide cyclase from Vibrio cholerae (DncV) responsible for synthesizing a hybrid cyclic GMP-AMP. [9]Structural view of the helicase reveals that Zika virus uses a conserved mechanism for unwinding RNA. [10]Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure.

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号